PGR and obesity disorder: Specifically, CUDC-907 was shown to (1) restore PR expression and resensitize tumors to hormone therapy, (2) reduce levels of the obesity-related factor IGF-1, and (3) inhibit the PI3K/Akt signaling pathway.